|
|
Candidate mechanisms for chemotherapy-induced neurocognitive deficits in pediatric solid non-CNS tumor patients |
| 5R21CA262491-02 |
|
NCI |
2022 |
|
|
Brain iron accumulation as an in vivo quantifiable biomarker of neurocognitive dysfunction in pediatric brain tumor survivors |
| 5R21CA262978-02 |
|
NCI |
2022 |
|
|
Developmental regulation of apoptosis as a modifiable driver of radiotherapy-induced neurocognitive impairment in pediatric patients |
| 5R37CA248565-03 |
|
NCI |
2022 |
|
|
Very-long Term Neurocognitive Outcomes in Breast Cancer Survivors (ProbC2) |
| 7R01CA172145-09 |
|
NCI |
2022 |
|
|
Identifying children with subclinical neurocognitive decline and susceptibility to oxidative damage during the early months of therapy for ALL |
| 7R01CA220568-05 |
|
NCI |
2022 |
|
|
Conformable, Expandable Neural Interface Device for the developing brain |
| 5R21EY032381-02 |
|
NEI |
2022 |
|
|
Developing A Transition MicroElelectrode Array for Large-scale Brain Recording |
| 5R21EY033082-02 |
|
NEI |
2022 |
|
|
Home sleep apnea testing compared to in-lab polysomnography for the evaluation of obstructive sleep apnea in children |
| 1R61HL162839-01 |
|
NHLBI |
2022 |
|
|
Treatment of Obstructive Sleep Apnea with Personalized Surgery in Children with Down Syndrome (TOPS-DS) |
| 1R61HL165345-01 |
|
NHLBI |
2022 |
|
|
Randomized Control Trial of oxygen therapy in Children and Adolescents with Down Syndrome and Obstructive Sleep Apnea |
| 1R61HL165366-01 |
|
NHLBI |
2022 |
